Fig.4.

Baseline (a, b) and follow-up CT-scan at 6 months (c, d) and 8 months (e, f) showing an adrenal metastasis (respectively a, c, e) and the liver (respectively b, d, f) in a mRCC patient under nivolumab. No liver lesion was observed on the initial workup (b). A liver lesion appeared after 6 months (d) despite decrease in other lesions (c). On the following workup, the lesion had disappeared, while observing further response of the other lesions. This represents an example of pseudo-progression. The patient went on to respond for 7 months under therapy.